Phase 2
Completed N=5
Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401
Source: ClinicalTrials.gov NCT02363439 ↗Enrolled (actual)
5
Serious AEs
0.0%
Results posted
Nov 2017
Primary outcomePrimary: Number of Participants With Adverse Events — 4 Participants
Summary
An extension study for patients who complete 24 weeks of IMO-8400 on study 8400-401.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Adverse Events |
4 | — |
Eligibility Criteria
Inclusion Criteria
- Completed 24 weeks of treatment in Protocol 8400-401
Exclusion Criteria
- Grade 3 (or higher) adverse event assessed as treatment-related at any time during the course of treatment under Protocol 8400-401.
- Has evidence of disease progression under Protocol 8400-401.
- Has received other anti-cancer therapies other than IMO-8400 since enrolling in Protocol 8400-401.
Data sourced from ClinicalTrials.gov (NCT02363439). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.